Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Oncotelic’s subsidiary Sapu Nano completed the initial three-patient safety cohort of its Phase 1b SP-03-B101 trial for Sapu003, an intravenous everolimus formulation. The independent Safety Review Committee observed no dose-limiting toxicities and recommended advancing to the next dose level.
Key figures
- Drug Name
- Sapu003
- Phase Of Trial
- Phase 1b
- Patent count
- 75
- Particle size nm
- <20
- Initial cohort size
- 3
- Patent applications
- 500
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.